Last Friday, the European Patent Office revoked (in its entirety) European Patent No. EP 1 230 375, owned by Cancer Research Therapeutics Ltd. of Cambridge, UK and exclusively licensed to Alnylam Pharmaceuticals, Inc. The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis Deutschland GmbH, Sirna Therapeutics, Nucleonics, Inc., Quark Biotech, and Silence Therapeutics AG.
The details can be read here. and here.
No comments:
Post a Comment